A method produces a coatable core for a modified release drug formulation for oral administration. The coatable core has a high drug load of at least 70 wt % based on the total weight of the coatable core. The method involves the steps of granulating a composition containing a drug and at least one binder to form granules; blending the granules with a pharmacologically acceptable disintegrant and optionally, one or more additional pharmacologically acceptable excipients, to form a compression blend, wherein the disintegrant is present in an amount from about 0.5 wt % to about 5 wt %, based on the total weight of the coatable core; and compressing the compression blend using an external lubrication compression method to form a coatable core.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
4.
TABLET HAVING HIGH CONTENT OF ACOTIAMIDE OR SALT THEREOF
The present invention addresses the problem of providing a tablet which contains acotiamide or a salt thereof at a high concentration and which has not only a good elution property but also good storage stability. The present invention relates to a tablet characterized by comprising granules that contain (A) acotiamide or a salt thereof, (B) pregelatinized starch, and (C) a disintegrant selected from low-substituted hydroxypropyl cellulose and sodium starch glycolate wherein the content of the component (A) in an uncoated tablet is 65-91 mass%.
To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.
To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.
The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances, namely, peppermint oil and peppermint oil capsules for treating diseases and disorders of the gastro-intestinal tract
The present invention relates to a solid oral dosage form for sustained release in the lower gastrointestinal tract, comprising antibodies or functional fragments thereof in a depot layer (2) covering an inert core unit (1), a sustained release layer (3) covering the depot layer, and a delayed release layer (4) covering the sustained release layer, preferably prepared by drug layering; an oral multiparticulate drug delivery system comprising a plurality of the solid oral dosage forms; and the use of the solid oral dosage form in the targeted local treatment in the lower gastrointestinal tract of a patient.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, in particular for the diagnosis, prevention and treatment of gastrointestinal disorders and conditions; pharmaceutical preparation for the treatment of inflammation; pharmaceutical preparations containing glucocorticoid steroids; dietetic substances in the nature of oral diagnostic preparations and oral pharmaceutical preparations adapted for medical use, in particular for the diagnosis, prevention and treatment of gastrointestinal disorders and conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations, namely, for diagnosis, prevention and treatment of gastrointestinal diseases and disorders, pharmaceutical products for treatment of inflammation; dietetic food and beverages for medical use, namely, for diagnosis, prevention and treatment of gastrointestinal disorders
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
Goods & Services
Pharmaceutical, medical and veterinary preparations and
substances; sanitary preparations for medical purposes;
plasters; bandages; materials for dressings; material for
stopping teeth; dental wax; antiseptics; disinfectants;
preparations for destroying vermin; fungicides; herbicides;
medicated oils and creams; antibiotic, antimicrobial and
antibacterial preparations and substances; antiseptics and
disinfectants; preparations and substances for the
prevention and treatment of diseases and disorders of the
gastrointestinal tract; medicated preparations and
substances for the conditioning, care and appearance of the
skin, body, face, eyes, hair, scalp, teeth and nails;
diagnostic preparations for medical purposes; diagnostic
reagents for clinical or medical laboratory use; assay kits
for clinical or medical laboratory use. Education; education in the field of pharmaceuticals,
gastroenterology, medicine and healthcare; education in the
field of diseases and disorders of the gastrointestinal
tract; providing of training; entertainment; providing
education and entertainment; sporting and cultural
activities; providing of non-downloadable news,
publications, recordings, entertainment, education,
programmes and other content; publishing and online
publishing; publishing of online, electronic, magnetic,
optical, digital, non-downloadable and non-printed blogs,
books, newspapers, magazines, articles, texts, newsletters,
feeds, web pages, web sites and, recordings; production of
radio, television and internet programmes; presentation of
radio, television and internet programmes; education,
training, cultural and entertainment services by providing
non-downloadable playback of audio, visual and audio-visual
recordings and content including via global communications
networks; providing education, training, entertainment, and
cultural content and information via a website; providing
non-downloadable, audio, visual and audio-visual recordings
and content; providing online non-downloadable electronic
publications via a web sites, databases, information, news
and commentary, including in the fields of pharmaceuticals,
gastroenterology, medicine and healthcare; organising and
operating games and competitions; online gaming services;
gaming services; lottery services; organising and operating
educational and entertainment events, shows and
competitions; arranging contests; publishing; music
publishing; recording services; music mixing services;
production of music, films and of recordings and of audio,
visual and audio-visual content; direction of music, films
and of performances; provision of educational examinations
for granting of qualifications and awards; organising and
operating award schemes and ceremonies including in the
fields of pharmaceuticals, gastroenterology, medicine and
healthcare; organising and conducting parties, festivals,
ceremonies, entertainment events and educational events;
performances and live performances [entertainment]; radio,
dramatic and television education and entertainment;
photography services and photographic syndication services;
photographic reporting; news and current events reporting
and syndication; educational and entertainment events
ticketing and ticket reservation services; providing
information in the fields of education and/or entertainment
via a global computer network; advice, information and
assistance relating to all the aforesaid; including (but not
limited to) any of the aforesaid services provided online,
and/or provided for use with and/or by way of the Internet,
the world wide web and/or via communications, telephone,
mobile telephone and/or wireless communication networks.
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
Goods & Services
Pharmaceutical, medical and veterinary preparations and
substances; sanitary preparations for medical purposes;
plasters; bandages; materials for dressings; material for
stopping teeth; dental wax; antiseptics; disinfectants;
preparations for destroying vermin; fungicides; herbicides;
medicated oils and creams; antibiotic, antimicrobial and
antibacterial preparations and substances; antiseptics and
disinfectants; preparations and substances for the
prevention and treatment of diseases and disorders of the
gastrointestinal tract; medicated preparations and
substances for the conditioning, care and appearance of the
skin, body, face, eyes, hair, scalp, teeth and nails;
diagnostic preparations for medical purposes; diagnostic
reagents for clinical or medical laboratory use; assay kits
for clinical or medical laboratory use. Education; education in the field of pharmaceuticals,
gastroenterology, medicine and healthcare; education in the
field of diseases and disorders of the gastrointestinal
tract; providing of training; entertainment; providing
education and entertainment; sporting and cultural
activities; providing of non-downloadable news,
publications, recordings, entertainment, education,
programmes and other content; publishing and online
publishing; publishing of online, electronic, magnetic,
optical, digital, non-downloadable and non-printed blogs,
books, newspapers, magazines, articles, texts, newsletters,
feeds, web pages, web sites and, recordings; production of
radio, television and internet programmes; presentation of
radio, television and internet programmes; education,
training, cultural and entertainment services by providing
non-downloadable playback of audio, visual and audio-visual
recordings and content including via global communications
networks; providing education, training, entertainment, and
cultural content and information via a website; providing
non-downloadable, audio, visual and audio-visual recordings
and content; providing online non-downloadable electronic
publications via a web sites, databases, information, news
and commentary, including in the fields of pharmaceuticals,
gastroenterology, medicine and healthcare; organising and
operating games and competitions; online gaming services;
gaming services; lottery services; organising and operating
educational and entertainment events, shows and
competitions; arranging contests; publishing; music
publishing; recording services; music mixing services;
production of music, films and of recordings and of audio,
visual and audio-visual content; direction of music, films
and of performances; provision of educational examinations
for granting of qualifications and awards; organising and
operating award schemes and ceremonies including in the
fields of pharmaceuticals, gastroenterology, medicine and
healthcare; organising and conducting parties, festivals,
ceremonies, entertainment events and educational events;
performances and live performances [entertainment]; radio,
dramatic and television education and entertainment;
photography services and photographic syndication services;
photographic reporting; news and current events reporting
and syndication; educational and entertainment events
ticketing and ticket reservation services; providing
information in the fields of education and/or entertainment
via a global computer network; advice, information and
assistance relating to all the aforesaid; including (but not
limited to) any of the aforesaid services provided online,
and/or provided for use with and/or by way of the Internet,
the world wide web and/or via communications, telephone,
mobile telephone and/or wireless communication networks.
The present invention relates to antibodies which bind to TNFα and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances, namely, peppermint oil and peppermint oil capsules for treating diseases and disorders of the gastro-intestinal tract
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
22.
SOLID ORAL DOSAGE FORM COMPRISING ANTIBODIES FOR SUSTAINED RELEASE IN THE LOWER GASTROINTESTINAL TRACT
The present invention relates to a solid oral dosage form for sustained release in the lower gastrointestinal tract, comprising antibodies or functional fragments thereof in a depot layer (2) covering an inert core unit (1), a sustained release layer (3) covering the depot layer, and a delayed release layer (4) covering the sustained release layer, preferably prepared by drug layering; an oral multiparticulate drug delivery system comprising a plurality of the solid oral dosage forms; and the use of the solid oral dosage form in the targeted local treatment in the lower gastrointestinal tract of a patient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
The present invention addresses the problem of developing a dysuria-alleviating agent that demonstrates sufficient dysuria-alleviating effects and can be administered over a long period of time. The invention relates to a dysuria-alleviating agent, which comprises acotiamide or a salt thereof as an active ingredient, and which is characterised by being used such that the acotiamide or a salt thereof is orally administered to an adult in an amount of 600 mg to 900 mg per day, each dose consisting of 200 mg to 300 mg.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and teaching apparatus and instruments; apparatus
for recording, transmission or reproduction of sound or
images; downloadable mobile applications for use in disease
management and tracking patient compliance with medical
treatments; downloadable software in the nature of mobile
application for providing and tracking information relating
to clinical trials, the enrollment of patients in clinical
trials, and available treatments for disease and disorders;
downloadable applications for mobile communication devices
featuring educational information in the field of
healthcare. Educational instruction; training; entertainment services;
sporting and cultural activities; arranging and conducting
of colloquiums, seminars, and workshops (training);
arranging and conducting of congresses, conferences and
lectures; publication of texts, included in this class;
publication of printed matter, including in electronic form,
all the aforesaid services included in this class; providing
of training and further training in the form of seminars,
conferences and congresses, including via the internet
(e-learning); human resources developed by basic and
advanced training (education); conducting educational
support programs for patients and health care professionals;
educational and training services relating to the use of
medical apparatus and devices; publication of information of
health disorders in the management of said disorders;
providing educational information in the medical field and
clinical trials to health care professionals. Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; design and development of computer hardware and
software; medical research, providing medical and scientific
research information in the field of health care via the
internet; providing scientific research information in the
medical field and clinical trials to health care
professionals; design of computer databases; development of
computer databases; development, updating and maintenance of
data bases; database services, namely computer programming;
technical organisational consultancy in connection with the
use of digital media and planning, development and
implementation of concepts for the use of digital media;
consultancy in the field of biological research,
bacteriological research, chemical research, medicinal
research, pharmaceutical research; engineering in the field
of biological research, bacteriological research, chemical
research, medicinal research, pharmaceutical research;
pharmaceutical analysis, chemical analysis, bacteriological
research; technical project studies, in particular in the
field of chemical research, medicinal research,
pharmaceutical research; laboratory services; consultancy,
assessment, research, testing, monitoring in the field of
biology, bacteriology, chemistry; certification services as
well as providing quality schemes for services, substances,
materials, products, documents and or information documents
being tested and monitoring of certified companies or
service providers; provision of information concerning
clinical study results and clinical study data by means of
interactive web sites; providing medical research
information in the medical field and clinical trials to
health care professionals; provision of scientific
information for physicians, patients and care givers via the
internet, digital media and databases; hosting of a website
as a desktop application and providing temporary use of
non-downloadable software applications accessible via a
website for mobile communication devices featuring
educational information in the field of healthcare. Medical services; animal healthcare services; hygienic and
beauty care for human beings or animals; agriculture,
horticulture and forestry services; providing support in the
observation, monitoring, adherence and compliance of
patients to medical treatments; providing a registry of
patients in the field of diseases; provision of medical
information by means of web sites, digital media and data
banks; providing medical services relating to the use of
medical apparatus, instruments and devices; providing health
information and medical information; providing medical
information relating health disorders and the management of
said disorders; medical diagnostic testing, monitoring and
reporting; medical services, namely providing internet-based
medical information for patients and medical issues and
procedures; medical services, namely providing medical
information about disease symptoms, medical experiences,
supporting community from an interactive patient and
caregiver platform; collection and preservation of
biological tissue, blood, cells; medical diagnostic
services; medical treatment services; providing information
and data for diagnosis and medical treatment; medical
analysis services.
25.
NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY
The present disclosure provides a composition for the prophylaxis or treatment of diseases (e.g., infectious disease, allergy or autoimmune disease). The present disclosure provides a composition, a medicament, a kit, and the like for the prophylaxis or treatment of the disease of a test subject. The composition, medicament, kit, and the like contain a non-causative factor antigen component that is neither derived from nor cross-reactive with the causative factor of the disease, and is administered under conditions where a causative factor antigen component derived from and/or cross-reactive with a causative factor of the target disease is present in the target.
The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering, optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention addresses the problem of providing a composition for an external preparation for skin, the composition: containing an ester-based steroid and gamma oryzanol, both the ester-based steroid component and the gamma oryzanol component being completely dissolved; retaining formulation stability and component stability even when stored for a long period of time; and suppressing skin irritation and having an excellent feeling when used. The present invention relates to a composition for an external preparation for skin, the composition containing the following components (A) to (C). (A) An ester-based steroid; (B) gamma oryzanol; and (C) a medium chain fatty acid triglyceride.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNFα), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations and substances, namely, preparations and substances for treating diseases and disorders of the gastro-intestinal tract Consulting services, namely, providing manufacturing assistance and advice in the field of drug manufacturing Pharmaceutical drug development services Consulting services, namely, providing regulatory compliance assistance with respect to the regulatory approval process for drugs
To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.
To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer.
The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.
The present disclosure provides a composition, a combination, a medical device, and the like, that use an extract from Mycobacterium tuberculosis and are a new modality for treating, preventing, or preventing the recurrence of a cancer or a tumor. The present disclosure provides a composition, a combination, and a medical device, that use an extract from Mycobacterium tuberculosis and are a new modality for treating, preventing, or preventing the recurrence of a cancer or a tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means.
The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
35.
Anti-TNF-alpha-antibodies and functional fragments thereof
The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and teaching apparatus and instruments; Apparatus for recording, transmission or reproduction of sound or images; Downloadable mobile applications for use in disease management and tracking patient compliance with medical treatments; downloadable software in the nature of mobile application for providing and tracking information relating to clinical trials, the enrollment of patients in clinical trials, and available treatments for disease and disorders. Educational instruction; Training; Entertainment services; Sporting and cultural activities; Arranging and conducting of colloquiums, seminars, and workshops (training); Arranging and conducting of congresses, conferences and lectures; Publication of texts, included in class 41; Publication of printed matter, Including in electronic form, All the aforesaid services included in class 41; Providing of training and further training in the form of seminars, conferences and congresses, including via the Internet (e-learning); Human resources developed by basic and advanced training (education); conducting educational support programs for patients and health care professionals; educational and training services relating to the use of medical apparatus and devices; publication of information of health disorders in the management of said disorders; Providing educational information in the medical field and clinical trials to health care professionals. Scientific and technological services and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software; medical research, providing medical and scientific research information in the field of health care via the internet; Providing scientific research information in the medical field and clinical trials to health care professionals; Construction of databases; Development, updating and maintenance of data bases; Database services, namely computer programming; Technical organisational consultancy in connection with the use of digital media and planning, development and implementation of concepts for the use of digital media; Consultancy in the field of biological research, bacteriological research, chemical research, medicinal research, pharmaceutical research; engineering in the field of biological research, bacteriological research, chemical research, medicinal research, pharmaceutical research; Pharmaceutical analysis, Chemical analysis, Bacteriological research; technical project studies, in particular in the field of chemical research, medicinal research, pharmaceutical research; Laboratory services; consultancy, assessment, research, testing, monitoring in the field of biology, bacteriology, chemistry; issuing certificates and/or quality schemes for the services, substances, materials, products, documents and/information documents being tested and monitoring of certified companies or service providers; provision of information concerning clinical study results and clinical study data by means of interactive web sites; providing medical research information in the medical field and clinical trials to health care professionals; provision of scientific information for physicians, patients and care givers via the internet, digital media and databases; Providing of a website as a desktop application and downloadable applications for mobile communication devices featuring educational information in the field of healthcare. Medical services; Animal healthcare services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services; providing support in the observation, monitoring, adherence and compliance of patients to medical treatments; providing a registry of patients in the field of diseases; provision of medical information by means of web sites, digital media and data banks; providing medical services relating to the use of medical apparatus, instruments and devices; providing health information and medical information; providing medical information relating health disorders and the management of said disorders; Medical diagnostic testing, monitoring and reporting; medical services, namely providing internet-based medical information for patients and medical issues and procedures; medical services, namely providing medical information about disease symptoms, medical experiences, supporting community from an interactive patient and caregiver platform; Collection and preservation of biological tissue, blood, cells; Medical diagnostic services; Medical treatment services; providing information and data for diagnosis and medical treatment; Medical analysis services.
Provided is a disinfectant composition that exhibits excellent long-term benzalkonium chloride stability and excellent adherence to articles. The present invention relates to a disinfectant composition having a pH from 6.0 to 7.0 and containing the following components (A) to (D). (A) 0.06 mass% to 0.2 mass% of benzalkonium chloride; (B) 0.005 mass% to 0.2 mass% of parabens; (C) 5 mass% to 30 mass% of ethanol; and (D) at least 0.3 mM but less than 10 mM of a pH buffer.
A01N 37/40 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system having at least one carboxylic group or a thio-analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 25/24 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
Nonprofit Organization North East Japan Study Group (Japan)
ZERIA PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Kobayashi, Kunihiko
Horii, Takayuki
Abstract
The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.
A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure provides a composition for preventing or treating a disease (for example, an infectious, allergic or autoimmune disease). The present disclosure provides a composition, a medicine, a kit, etc. for preventing or treating the aforesaid disease of a subject. The composition, medicine, kit, etc. are characterized by containing a non-causative factor antigen component, which is neither derived from the causative factor of the disease nor cross-reactive with the causative factor, and being to be administered under conditions where a causative factor antigen component derived from the causative factor of the target disease and/or cross-reactive with the causative factor is present in the subject.
The present disclosure provides a composition for treating or preventing a disease (for example, an infection, an allergy, or an autoimmune disease). The present disclosure provides a composition, a medicinal drug, or a kit for treating or preventing said disease in a patient. The composition, the medicinal drug, or the kit is characterized by containing a non-causative factor antigen component that is not derived from a causative factor of the disease and that does not cross-react with the causative factor. The composition is characterized by being administered in the presence of a causative factor antigen component that is derived from a causative factor of the disease to be targeted in a subject and/or that cross-reacts with the causative factor.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, for the diagnosis, prevention and/or treatment of gastrointestinal disorders and conditions; pharmaceutical preparation for the treatment of inflammation of the gastrointestinal tract; dietetic substances in the nature of dietetic foods adapted for medical use, namely, for the diagnosis, prevention and/or treatment of gastrointestinal disorders and conditions
47.
TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF
The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present disclosure provides a composition, a combination, a medical device, and the like, that use an extract from Mycobacterium tuberculosis and are a new modality for treating, preventing, or preventing the recurrence of a cancer or a tumor. The present disclosure provides a composition, a combination, and a medical device, that use an extract from Mycobacterium tuberculosis and are a new modality for treating, preventing, or preventing the recurrence of a cancer or a tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means.
A method produces a coatable core for a delayed release drug formulation for oral administration, to deliver a drug to the colon. The method involves forming a core containing a drug. An outer layer coating preparation is formed by combining a first aqueous preparation of an enzymatically degradable polymer, which is degradable by colonic bacterial enzymes; a second aqueous preparation of a film-forming enteric polymer having a pH threshold of about pH 6 or above; and an organic anti-tack agent. The core is then coated with the outer layer coating preparation to form an outer layer coated core.
A delayed release drug formulation for oral administration delivers a drug to the colon of a subject. The formulation includes a core containing a drug and a coating for the core. The coating contains an outer layer and an inner layer. The outer layer contains a film-forming enteric polymer having a pH threshold at about pH 6 or above, and the inner layer contains a film-forming non-ionic polymer that is soluble in intestinal or gastrointestinal fluid and a buffer agent in an amount from more than 20 wt % to about 60 wt % based on the dry weight of the non-ionic polymer.
A method produces a coatable core for a modified release drug formulation for oral administration. The coatable core has a high drug load of at least 70 wt % based on the total weight of the coatable core. The method involves the steps of granulating a composition containing a drug and at least one binder to form granules; blending the granules with a pharmacologically acceptable disintegrant and optionally, one or more additional pharmacologically acceptable excipients, to form a compression blend, wherein the disintegrant is present in an amount from about 0.5 wt % to about 5 wt %, based on the total weight of the coatable core; and compressing the compression blend using an external lubrication compression method to form a coatable core.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A delayed release drug formulation contains a core containing a drug and a delayed release coating for intestinal release, where release of the drug in the colon is not hindered by the absence of an alkaline middle layer between the core and the outer layer. The delayed release coating contains an outer coating, and optionally, an isolation layer. The outer coating contains a mixture of an enzymatically degradable polysaccharide which is degradable by colonic enzymes selected from the group of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, dextran, ptallulan, carrageenan, scleroglucan, curdulan, and levan and a film-forming enteric polymer having a pH threshold at about pH 6 or above. The enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of more than 60:40.
NONPROFIT ORGANIZATION NORTH EAST JAPAN STUDY GROUP (Japan)
ZERIA PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Kobayashi, Kunihiko
Horii, Takayuki
Abstract
The present disclosure provides a composition, a combination product, a medical device and the like for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor. The present disclosure provides a composition, a combination product and a medical device for treating or preventing cancer or a tumor or preventing the recurrence of the cancer or the tumor, each of which comprises an immune checkpoint inhibitor and a dendritic cell direct activator or means. In another aspect, the present disclosure provides: a novel cancer treatment method which comprises carrying out a treatment of cancer by employing a combination of a treatment by the administration of an immune checkpoint inhibitor and a treatment for improving the sensitivity to the immune checkpoint inhibitor and, therefore, can be used as an immunotherapy that can be expected to have an excellent therapeutic effect; and a medicine which can be used for the cancer treatment method.
A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
A61P 43/00 - Drugs for specific purposes, not provided for in groups
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, preparations for the prevention and treatment of gastrointestinal disorders; diagnostic products for medical use, namely, diagnostic preparations for medical use
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japan)
ZERIA PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Ishii, Ken
Kobayashi, Nobuyoshi
Ohira, Yuta
Seto, Koichi
Abstract
The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or symptom. The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or symptom in a subject, said composition comprising an antigen component, which is specific to the subject (or immunological memory of which remains in the subject), against a component which is different from a causative factor of the disease, disorder or symptom.
The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering, optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided is a stable oil-in-water emulsified composition containing three components: urea, an ester steroid, and allantoin. An oil-in-water emulsified composition containing the following components (A)-(D) and having a pH of 5-6. (A) Urea: 0.5-10 mass%, (B) an ester steroid: 0.05-0.3 mass%, (C) allantoin: 0.1-1 mass%, and (D) an amino acid or a salt thereof: 1-10 mass%
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
63.
Anti-TNF-α-antibodies and functional fragments thereof
The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to antibodies which bind to TNFα and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
65.
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by wet granulation, extrusion and spheronization, optionally coated with a delayed release coating the solid dosage forms prepared by the method and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A method of producing a coatable core for a delayed release drug formulation for oral administration to deliver a drug to the colon. The method comprises forming a core comprising a drug. An outer layer coating preparation is formed by combining a first aqueous preparation of an enzymatically degradable polymer which is degradable by colonic bacterial enzymes; a second aqueous preparation of a film-forming enteric polymer having a pH threshold of about pH 6 or above; and an organic anti-tack agent. The core is then coated with the outer layer coating preparation to form an outer layer coated core.
In a delayed release drug formulation comprising a core containing a drug and optionally and a delayed release coating for intestinal release, release of the drug in the colon is not hindered by the absence of an alkaline middle layer between the core and the outer layer. The delayed release coating comprising and inner coating and optionally an isolation layer. The outer coating comprises a mixture of an enzymatically degradable polysaccharide which is degradable by colonic enzymes selected from the group consisting of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, d extra n, pullulan, carrageenan, scleroglucan, chitin, curdulan, and levan; and a film-forming enteric polymer having a pH threshold at about pH 6 or above, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of more than 60:40.
The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNFα), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject. The formulation comprises a core comprising and drug and coating for the core. The coating comprises an outer layer and an inner layer. The outer layer comprises a film- forming enteric polymer having a pH threshold at about pH 6 or above and the inner layer comprises a film-forming non-ionic polymer that is soluble in intestinal or gastrointestinal fluid, and a buffer agent in an amount from more than 20 wt % to about 60 wt %, based on the dry weight of the non-ionic polymer.
A method of producing a coatable core for a modified release drug formulation for oral administration. The coatable core has a high drug load of at least 70 wt % based on the total weight of the coatable core. The method comprises the steps of granulating a composition comprising a drug and at least one binder to form granules; blending the granules with a pharmacologically acceptable disintegrant and optionally one or more additional pharmacologically acceptable excipients to form a compression blend, wherein the disintegrant is present in an amount from about 0.5 wt % to about 5 wt %, based on the total weight of the coatable core; and compressing the compression blend using an external lubrication compression method to form a coatable core.
A process for manufacturing 5-aminosalicylic acid (5-ASA) tablet cores. The process comprises the steps of wet granulating a granulation composition comprising 5-ASA, a granulation liquid, and at least one binder using a high-shear granulator to form 5-ASA granules; drying the 5-ASA granules to form dry granules; blending the dry granules with at least one filler and optionally one or more additional pharmaceutical excipients to form a compression blend; and compressing the compression blend to form 5-ASA tablet cores. The granulation composition and the compression blend do not comprise a reducing sugar.
The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNFα), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
78.
We Care Ulcerative Colitis Crohn's Disease Microscopic Colitis Bowel Cleansing Irritable Bowel Syndrome
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education; training; entertainment; sporting and cultural
activities; organizing and conducting colloquiums, seminars
and workshops (training); organizing and conducting
congresses, conferences and presentations; publication of
texts other than advertising texts; publication of printed
products, including in electronic form; training and
further education in the form of seminars, conferences and
congresses, including on the Internet (e-learning); basic
and advanced training for human resources development
(education); conducting educational support programs for
training and education for patients and healthcare
professionals; education and training services related to
the use of medical apparatus and devices; publication of
information on health problems and information for the
management of gastrointestinal diseases and disorders and
inflammatory conditions of the gastrointestinal tract;
providing educational information relating to health care
via a website in the form of office applications and
downloadable applications for mobile communication devices;
providing health care professionals with educational
information in the clinical trial and medical field. Scientific and technological services as well as research
and design services relating thereto; industrial analysis
and research services; design and development of computers
and software; medical research, providing information on
medical and scientific research in the field of health care
via the Internet; providing healthcare professionals with
information related to scientific research in the clinical
trial and medical field; construction of computer
databases; development, updating and maintenance of
computer database software; data bank services, namely,
creation of computer programs; technical consulting related
to the use of digital media as well as study, development
and transposition of concepts for the use of digital media;
assistance in the field of biological research,
bacteriological research, chemical research, medical
research, pharmaceutical research; engineering in the field
of biological research, bacteriological research, chemical
research, medical research, pharmaceutical research;
conducting medical and pharmaceutical analysis for
scientific research; technical project studies,
particularly in the field of chemical research, medical
research, pharmaceutical research; chemical, medical and
biological laboratory services for scientific research;
assistance, evaluation, research, testing, monitoring in the
field of biology, bacteriology, chemistry; delivery of
certificates and/or quality standards for services,
substances, materials, products, and informational material
and documents which are tested and inspected by certified
companies or certified service providers; providing research
information about clinical trial results and clinical trial
data through interactive web sites; providing healthcare
professionals with information related to medical research
in the clinical trial and medical field; providing
scientific information for doctors, patients and healthcare
personnel via the Internet, digital media and databases;
service providers and provision of technical advice in the
field of design, development and use of software, computer
hardware and information technology systems. Medical services; veterinary services; hygienic and beauty
care for human beings or animals; agriculture, horticulture
and forestry services; providing assistance for
observation, monitoring adherence and compliance of medical
treatments of patients; provision of medical information
via websites, digital media and data banks; provision of
medical services relating to the use of medical devices,
apparatus and instruments; providing medical and health
information; provision of information on health problems
and information for the management of gastrointestinal
diseases and disorders and inflammatory conditions of the
gastrointestinal tract; testing, monitoring and reporting
of medical diagnostics; medical services, namely providing
medical information on the Internet for patients on
operations and medical matters; medical services, namely
providing medical information on the symptoms of diseases,
medical experiments, community assistance via an interactive
platform for patients and nursing staff; collection and
conservation of biological tissue, blood, cells; medical
diagnosis services; medical care services; provision of
information and data for medical diagnosis and treatment;
medical, chemical and biological laboratory services for
medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Pharmaceutical preparations, namely, preparations and substances for treating diseases and disorders of the gastro-intestinal tract. (1) Pharmaceutical drug development services; fitness, medical, and pharmaceutical research services.
(2) Consulting services, namely, providing regulatory compliance assistance with respect to the regulatory approval process for drugs; licensing of intellectual property; legal services.
05 - Pharmaceutical, veterinary and sanitary products
32 - Beers; non-alcoholic beverages
Goods & Services
Pharmaceutical preparations; tonics for medical purposes;
nutritional supplements; dietary supplements for humans;
dietary supplemental drinks for humans. Non-alcoholic beverages; soft drinks; fruit drinks and fruit
juices; non-alcoholic vegetable juice beverages; whey
beverages.
83.
DIPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
Provided is a novel anti-inflammatory agent. This anti-inflammatory agent has as an active ingredient a dipeptide selected from among: (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, D)Pro-(D)Leu, (D)Val-(D)Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp, (D)Ile-(D)Hyp, (D)Val-(D)Hyp, (D)Asp-(D)Ile, (D)Asp-(D)Val, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Ile-(L)Pro, (D)Leu-(L)Pro, (D)Pro-(L)Ile, (D)Pro-(L)Leu, (D)Val-(L)Pro, (D)Pro-(L)Val, (D)Leu-(L)Hyp, (D)Ile-(L)Hyp, (D)Val-(L)Hyp, (D)Asp-(L)Ile, (D)Asp-(L)Val, (D)Asp-(L)Leu, and (D)Asp-(L)Phe.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
A cognitive decline inhibitor or a learning ability improver is provided, which comprises, as an active ingredient, a liver hydrolysate having a lipid content of less than 2 mass % or a phosphatidylcholine content of less than 1 mass %.
A61P 25/00 - Drugs for disorders of the nervous system
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 9/00 - Medicinal preparations characterised by special physical form
A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; tonics for medical purposes;
nutritional supplements; dietary supplements for humans;
dietary supplemental drinks for humans.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; tonics for medical purposes;
nutritional supplements; dietary supplements for humans;
dietary supplemental drinks for humans.
88.
PREPARATION OF SOLID DOSAGE FORMS COMPRISING ANTIBODIES BY SOLUTION/SUSPENSION LAYERING
The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies andfunctional fragments thereof, by solution/suspension layering,optionally coated with a delayed release coating;the solid dosage forms prepared bythe method;and the use of the solid dosage forms inthe topical treatment in the gastrointestinal tract of a patient.
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn- binding. The antibodies of the invention have good effector functions and/orpharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
90.
PREPARATION OF SUSTAINED RELEASE SOLID DOSAGE FORMS COMPRISING ANTIBODIES BY SPRAY DRYING
The present invention relates to a method for preparing individual solid particles by spray drying, comprising antibodies and functional fragments thereof and sustained release polymers, suitable to be processed into sustained release solid dosage forms, optionally coated with a delayed release coating; the particles and solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to antibodies which bind to TNFα and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 37/00 - Drugs for immunological or allergic disorders
93.
METHOD FOR PREPARING A SOLID DOSAGE FORM COMPRISING ANTIBODIES BY WET GRANULATION, EXTRUSION AND SPHERONIZATION
The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by wet granulation, extrusion and spheronization,optionally coated with a delayed release coating the solid dosage forms prepared by the method and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn- binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
95.
TOPICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTIBODIES AND FRAGMENTS THEREOF
The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNFα), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances, namely, peppermint oil and peppermint oil capsules for treatment of disorders of the gastro intestinal tract
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical products,
namely, for the diagnosis, prevention and/or treatment of
gastrointestinal diseases and disorders; pharmaceutical
products for the treatment of inflammations of the
gastrointestinal tract.
[Problem] To provide a disinfectant composition belonging to the category of disinfectants to be used for sterilizing fingers, etc., said disinfectant composition containing chondroitin sulfate or a chondroitin sulfate salt as a moisturizing agent and thus having an improved moisturizing effect, being capable of preventing chapped hand skin causing bacterial or viral invasion and infection, and ensuring the uniform dispersion of the chondroitin sulfate or chondroitin sulfate salt in the composition. [Solution] A disinfectant composition characterized by comprising 20-60 wt% of a lower alcohol having 1-3 carbon atoms, 40-65 wt% of water and 0.006-1 wt% of chondroitin sulfate or a chondroitin sulfate salt; a disinfectant composition comprising an oily component, a thickener and a surfactant and having a viscosity of 50-300 Pa.s at 25°C; etc.
A61K 8/84 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions other than those involving only carbon-to-carbon unsaturated bonds
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and teaching apparatus and instruments; apparatus
for recording, transmission or reproduction of sound or
images; downloadable mobile applications for therapeutic
management and monitoring of patients' adherence to medical
treatments; downloadable software in the form of mobile
applications for providing and tracking information relating
to clinical trials, enrollment of patients in clinical
trials and available treatments for diseases and disorders. Education; training; entertainment; sporting and cultural
activities; organizing and conducting colloquiums, seminars
and workshops (training); organizing and conducting
congresses, conferences and presentations; publication of
texts other than advertising texts; publication of printed
products, including in electronic form; training and
further education in the form of seminars, conferences and
congresses, including on the Internet (e-learning); human
resources developed through basic and advanced training
(education); conducting educational assistance programs for
patients and health care professionals; education and
training services related to the use of medical apparatus
and devices; publication of information on health problems
for the management of the aforementioned problems;
providing a website and downloadable desktop applications
for mobile communication devices; providing health care
professionals with educational information in the clinical
trial and medical field. Scientific and technological services as well as research
and design services relating thereto; industrial analysis
and research services; design and development of computers
and software; medical research, providing information on
medical and scientific research in the field of health care
via the Internet; providing healthcare professionals with
information related to scientific research in the clinical
trial and medical field; construction of computer
databases; development, update and maintenance of
databases; data bank services, namely, creation of computer
programs; technical consulting in organizing related to the
use of digital media as well as study, development and
transposition of concepts for the use of digital media;
assistance in the field of biological research,
bacteriological research, chemical research, medical
research, pharmaceutical research; engineering in the field
of biological research, bacteriological research, chemical
research, medical research, pharmaceutical research;
conducting medical and pharmaceutical analyses for science,
chemical analysis, bacteriology researches; technical
project studies, particularly in the field of chemical
research, medical research, pharmaceutical research;
chemical, medical and biological laboratory services for
science; assistance, evaluation, research, testing,
monitoring in the field of biology, bacteriology, chemistry;
issuing of certificates and/or grade strains for tested
services, substances, materials, products, documents and/or
informational documents and monitoring of approved service
providers or companies; providing information about
clinical trial results and clinical trial data through
interactive web sites; providing healthcare professionals
with information related to medical research in the clinical
trial and medical field; providing scientific information
for doctors, patients and healthcare personnel via the
Internet, digital media and databases.
05 - Pharmaceutical, veterinary and sanitary products
32 - Beers; non-alcoholic beverages
Goods & Services
Pharmaceutical preparations; tonics for medical purposes;
nutritional supplements; dietary supplements for humans;
dietary supplemental drinks for humans. Non-alcoholic beverages; soft drinks; fruit drinks and fruit
juices; non-alcoholic vegetable juice beverages; whey
beverages.
